95 related articles for article (PubMed ID: 3127585)
21. Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.
Giannini EH; Barron KS; Spencer CH; Person DA; Baum J; Bernstein BH; Kredich DW; Jacobs JC; Zemel LS; Gibbas D
J Rheumatol; 1991 Aug; 18(8):1240-2. PubMed ID: 1941832
[TBL] [Abstract][Full Text] [Related]
22. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
[TBL] [Abstract][Full Text] [Related]
23. Auranofin: first choice for remission-inducing drug (RID) therapy in rheumatoid arthritis?
Bandilla K; Missler B; Klein-Reesink B
Scand J Rheumatol Suppl; 1986; 63():47-54. PubMed ID: 3474777
[TBL] [Abstract][Full Text] [Related]
24. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin.
Menard HA; Beaudet F; Davis P; Harth M; Percy JS; Russell AS; Thompson JM
J Rheumatol Suppl; 1982; 8():179-83. PubMed ID: 6813482
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis.
Hartman M; van Ede A; Severens JL; Laan RF; van de Putte L; van der Wilt GJ
J Rheumatol; 2004 May; 31(5):902-8. PubMed ID: 15124248
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of intensive exercise therapy directly following hospital discharge in patients with arthritis: results of a randomized controlled clinical trial.
Bulthuis Y; Mohammad S; Braakman-Jansen LM; Drossaers-Bakker KW; van de Laar MA
Arthritis Rheum; 2008 Feb; 59(2):247-54. PubMed ID: 18240191
[TBL] [Abstract][Full Text] [Related]
27. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
29. Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial.
Borg G; Allander E; Berg E; Brodin U; From A; Trang L
J Rheumatol; 1991 Jul; 18(7):1015-20. PubMed ID: 1920306
[TBL] [Abstract][Full Text] [Related]
30. Quality of life in patients receiving auranofin therapy: confirmation of efficacy using nontraditional health status measures.
Morgan GJ
Scand J Rheumatol Suppl; 1986; 63():29-35. PubMed ID: 3299681
[TBL] [Abstract][Full Text] [Related]
31. [Auranofin in the treatment of rheumatoid arthritis: a multicenter double-blind prospective clinical trial].
Yang JL
Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):486-8. PubMed ID: 8275829
[No Abstract] [Full Text] [Related]
32. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis.
Carette S; Calin A; McCafferty JP; Wallin BA
Arthritis Rheum; 1989 Feb; 32(2):158-65. PubMed ID: 2645874
[TBL] [Abstract][Full Text] [Related]
33. Measuring costs and financial benefits in randomized controlled trials.
Bulpitt CJ; Fletcher AE
Am Heart J; 1990 Mar; 119(3 Pt 2):766-70; discussion 770-1. PubMed ID: 2106770
[TBL] [Abstract][Full Text] [Related]
34. Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments.
Johnsen V; Borg G; Trang LE; Berg E; Brodin U
Scand J Rheumatol; 1989; 18(5):251-60. PubMed ID: 2688083
[TBL] [Abstract][Full Text] [Related]
35. A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis.
Vischer TL
Ann Rheum Dis; 1988 Jul; 47(7):582-7. PubMed ID: 3041924
[TBL] [Abstract][Full Text] [Related]
36. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group.
Giannini EH; Brewer EJ; Kuzmina N; Shaikov A; Wallin B
Arthritis Rheum; 1990 Apr; 33(4):466-76. PubMed ID: 2183804
[TBL] [Abstract][Full Text] [Related]
37. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis.
Glennås A; Kvien TK; Andrup O; Clarke-Jenssen O; Karstensen B; Brodin U
Br J Rheumatol; 1997 Aug; 36(8):870-7. PubMed ID: 9291856
[TBL] [Abstract][Full Text] [Related]
38. [A multi-center double blind prospective study of ridaura in the treatment of rheumatoid arthritis].
Zhang NZ
Zhonghua Nei Ke Za Zhi; 1992 Jul; 31(7):394-7, 443. PubMed ID: 1298591
[TBL] [Abstract][Full Text] [Related]
39. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group.
Bombardier C; Raboud J
Control Clin Trials; 1991 Aug; 12(4 Suppl):243S-256S. PubMed ID: 1663860
[TBL] [Abstract][Full Text] [Related]
40. [Auranofin in the treatment of rheumatoid arthritis. Report of 63 cases].
Tao XL; Dong Y; Zhang NZ
Zhonghua Nei Ke Za Zhi; 1987 Jul; 26(7):390-3, 444. PubMed ID: 3428027
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
